The global retinal disorder treatment market is anticipated to grow at a CAGR of 11.2% during the forecast period (2023-2030). Retinal disorders have both high prevalence and incidence in the geriatric population and diabetic patients, boosting the retinal disorder treatment market. According to the National Institute of Health (NIH), in April 2022, the major issue in the elderly population is the high prevalence of sight-threatening conditions, age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and cataracts. AMD is the leading cause of blindness in elderly patients in developed countries. In 2020, approximately 196 million people globally were affected by AMD, with a global prevalence of 8.7%. According to the latest predictions, the number of AMD patients will increase to 288 million people in 2040, as a consequence of the exponential increase in population ageing.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/retinal-disorder-treatment-market
Geographic atrophy has a devastating impact on patients’ lives and can lead to irreversible vision loss. For instance, in August 2023, Astellas Pharma Inc. announced the US (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY, a new complement C5 inhibitor, is the only approved GA treatment with a statistically significant reduction (p<0.01) in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.
Preclinical assets include an intravitreally based program for dry age-related macular degeneration and a program that targets cone-rod dystrophy. For instance, in June 2023, Beacon Therapeutics launched retinal disease gene therapies. Beacon’s lead clinical asset is AGTC-501, a gene therapy program in phase 2 clinical trials for the treatment of X-linked retinitis pigmentosa (XLRP). Preclinical assets include therapies for dry age-related macular degeneration and cone-rod dystrophy.
Retinopathy of prematurity is a leading cause of childhood blindness globally. Mild cases of retinopathy of prematurity (ROP) may improve without treatment, but some cases require treatment to keep ROP from causing significant visual impairment and even blindness. For instance, in February 2023, Regeneron Pharmaceuticals, Inc. announced that the US FDA has approved EYLEA® (aflibercept) Injection to treat preterm infants with retinopathy of prematurity. Following this first pediatric approval, EYLEA was indicated to treat five retinal conditions caused by ocular angiogenesis.
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered-
o By Indication
o By Dosage Form
o By Distribution Channel
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- includes Allergan, Inc., Bausch Health Companies Inc., Genentech, Inc., Novartis AG, and Regeneron Pharmaceuticals, Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Retinal Disorder Treatment Market Report Segment
By Indication
- Diabetic Retinopathy
- Macular Degeneration
- Retinal Detachment
- Retinoblastoma
- Other (Diabetic Eye Disease, Macular Pucker, Macular Hole, Floaters)
By Dosage Form
- Gels
- Eye Solutions
- Capsules & Tablets
- Eye Drops
- Ointments
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
A full report of Retinal Disorder Treatment Market available @ https://www.omrglobal.com/industry-reports/retinal-disorder-treatment-market
Global Retinal Disorder Treatment Market Report Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Adverum Biotechnologies
- Aldeyra Therapeutics, Inc.
- Alimera Sciences Inc.
- Bausch Health Companies Inc.
- Biogen Inc.
- Clearside Biomedical, Inc.
- Hoffmann-La Roche AG
- Genentech, Inc.
- Graybug Vision, Inc.
- Gyroscope Therapeutics Holdings PLC
- Iveric Bio, Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
